RxDoctor Payments Data

Katie Hudgens, MD

Internal Medicine · Adel, GANPI 1376076505

Payments from drug & device makers

$586in general payments, 2019–2025

Across 31 payments — averaging $18.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$192
  • Dexcom, Inc.$111
  • Lilly USA, LLC$62
  • GSK$46
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$35
  • AstraZeneca$28
  • plus $112 from 6 others

What the payments were for

  • Food & beverage$586100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$586 in reported general payments places this provider in the 55th percentile of 3,311 internal medicine providers in Georgia.

See all internal medicine providers in Georgia

Medicare billing

Part B allowed, 2024
$5,392
Medicare patients
37
Services billed
55

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide121$148,053
TrulicityDulaglutide38$50,632
OzempicSemaglutide34$40,920
XareltoRivaroxaban18$18,693
LinzessLinaclotide22$18,540
VraylarCariprazine Hcl11$18,491
JardianceEmpagliflozin29$17,814
EliquisApixaban38$17,521
EntrestoSacubitril/Valsartan18$16,605
FarxigaDapagliflozin Propanediol16$10,609
Breo ElliptaFluticasone/Vilanterol15$9,051
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog18$8,769
Spiriva RespimatTiotropium Bromide13$6,539
MovantikNaloxegol Oxalate26$5,761
Advair HfaFluticasone Propion/Salmeterol13$4,474

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity, Humalog$62$199,684172 claims
Novo NordiskOzempic$192$40,92034 claims
AstraZenecaFarxiga$28$10,60916 claims
GSKBreo Ellipta$46$9,05115 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 3,311 internal medicine providers in Georgia.

Other internal medicine in Adel

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →